SEC Company Response from Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Jul 6, 2017
Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: July 6, 2017 · CIK: 0001130166 · Accession: 0001571049-17-006525
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218305
Referenced dates: July 6, 2017
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance Re: Cyclacel Pharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed June 30, 2017 File No. 333-218305
Dear Ms. Hayes:
We are submitting this letter on behalf of Cyclacel Pharmaceuticals, Inc. (the “Company”) in response to comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) received by letter dated July 6, 2017 (the “Comment Letter”) from the Division of Corporate Finance and Office of Healthcare and Insurance, to Spiro Rombotis, the Company’s Chief Executive Officer, relating to the above-referenced registration statement on Form S-1 of the Company filed with the Commission on June 30, 2017 (the “Registration Statement”).
For convenient reference, we have set forth below in italics the Staff’s comment set forth in the Comment Letter and have keyed the Company’s response to the numbering of the comment and the heading used in the Comment Letter. This letter is being filed with the Commission with Amendment No. 2 to the Registration Statement (the “Amended Registration Statement”). Any capitalized terms used herein, but not defined shall have the meanings ascribed to them in the Amended Registration Statement. The response is based on information provided to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. by representatives of the Company. Page numbers referred to in this response reference the applicable pages of the Amended Registration Statement.
Exhibits, page II-3
1. Please have counsel revise the legal opinion to opine on the Class A Units and Class B Units that are included in the registration statement. For guidance, please refer to Section II.B.1.h of Staff Legal Bulletin No. 19.
Response: In response to the Staff’s comment, the Company has revised the legal opinion in the Amended Registration Statement accordingly.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Boston | London | Los Angeles | New York | San Diego | San Francisco | Stamford | Washington
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
United States Securities and Exchange Commission
July 6, 2017
Page 2
* * * * *
We hope that the above response will be acceptable to the Staff. Please do not hesitate to contact me at 212-692-6774 or jipapernik@mintz.com with any comments or questions regarding the Amended Registration Statement and this letter. We thank you for your time and attention.
Sincerely,
/s/ Joel I. Papernik
Show Raw Text
CORRESP
1
filename1.htm
Joel I. Papernik | 212 692 6774 | jipapernik@mintz.com
Chrysler Center
666 Third Avenue
New York, NY 10017
212-935-3000
212-983-3115 fax
www.mintz.com
July 6, 2017
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director, Office of Healthcare
and Insurance
Re: Cyclacel Pharmaceuticals, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed June 30, 2017
File No. 333-218305
Dear Ms. Hayes:
We are submitting this
letter on behalf of Cyclacel Pharmaceuticals, Inc. (the “Company”) in response to comments from the staff (the
“Staff”) of the Securities and Exchange Commission (the “Commission”) received by letter
dated July 6, 2017 (the “Comment Letter”) from the Division of Corporate Finance and Office of Healthcare and
Insurance, to Spiro Rombotis, the Company’s Chief Executive Officer, relating to the above-referenced registration statement
on Form S-1 of the Company filed with the Commission on June 30, 2017 (the “Registration Statement”).
For convenient reference,
we have set forth below in italics the Staff’s comment set forth in the Comment Letter and have keyed the Company’s
response to the numbering of the comment and the heading used in the Comment Letter. This letter is being filed with the Commission
with Amendment No. 2 to the Registration Statement (the “Amended Registration Statement”). Any capitalized
terms used herein, but not defined shall have the meanings ascribed to them in the Amended Registration Statement. The response
is based on information provided to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. by representatives of the Company. Page
numbers referred to in this response reference the applicable pages of the Amended Registration Statement.
Exhibits, page II-3
1. Please have counsel revise the legal opinion to opine on the Class A Units and Class B Units that are included in the registration
statement. For guidance, please refer to Section II.B.1.h of Staff Legal Bulletin No. 19.
Response: In response to the Staff’s
comment, the Company has revised the legal opinion in the Amended Registration Statement accordingly.
Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C.
Boston
| London | Los Angeles | New York | San Diego | San Francisco | Stamford | Washington
Mintz, Levin,
Cohn, Ferris, Glovsky and Popeo, P.C.
United States Securities and Exchange Commission
July 6, 2017
Page 2
* * * * *
We hope that the above response will be
acceptable to the Staff. Please do not hesitate to contact me at 212-692-6774 or jipapernik@mintz.com with any comments or questions
regarding the Amended Registration Statement and this letter. We thank you for your time and attention.
Sincerely,
/s/ Joel I. Papernik
Joel I. Papernik
cc:
Securities and Exchange Commission
Suzanne Hayes
Johnny Gharib
Erin Jaskot
Cyclacel Pharmaceuticals, Inc.
Spiro Rombotis, Chief Executive Officer